- Home
- DNTH vs MEGI Comparison
DNTH vs MEGI Comparison
Compare DNTH & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- MEGI
- Stock Information
- Founded
- DNTH 2015
- MEGI 2021
- Country
- DNTH United States
- MEGI United States
- Employees
- DNTH N/A
- MEGI N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- MEGI Investment Managers
- Sector
- DNTH Health Care
- MEGI Finance
- Exchange
- DNTH Nasdaq
- MEGI Nasdaq
- Market Cap
- DNTH 724.8M
- MEGI 647.0M
- IPO Year
- DNTH N/A
- MEGI N/A
- Fundamental
- Price
- DNTH $23.67
- MEGI $12.65
- Analyst Decision
- DNTH Strong Buy
- MEGI
- Analyst Count
- DNTH 9
- MEGI 0
- Target Price
- DNTH $46.43
- MEGI N/A
- AVG Volume (30 Days)
- DNTH 198.9K
- MEGI 178.0K
- Earning Date
- DNTH 03-20-2025
- MEGI 01-01-0001
- Dividend Yield
- DNTH N/A
- MEGI 11.40%
- EPS Growth
- DNTH N/A
- MEGI N/A
- EPS
- DNTH N/A
- MEGI N/A
- Revenue
- DNTH $5,366,000.00
- MEGI N/A
- Revenue This Year
- DNTH $100.14
- MEGI N/A
- Revenue Next Year
- DNTH N/A
- MEGI N/A
- P/E Ratio
- DNTH N/A
- MEGI N/A
- Revenue Growth
- DNTH 51.41
- MEGI N/A
- 52 Week Low
- DNTH $18.35
- MEGI $10.63
- 52 Week High
- DNTH $33.77
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- DNTH 53.31
- MEGI 54.45
- Support Level
- DNTH $22.77
- MEGI $12.50
- Resistance Level
- DNTH $25.46
- MEGI $12.67
- Average True Range (ATR)
- DNTH 1.49
- MEGI 0.16
- MACD
- DNTH 0.13
- MEGI 0.03
- Stochastic Oscillator
- DNTH 57.18
- MEGI 91.75
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
MainStay CBRE Global Infrastructure Megatrends Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It invests predominantly in income-producing equity securities issued by infrastructure companies, including common stock, preferred stock, convertible securities, and rights or warrants to buy common stocks. The company intends to focus on three infrastructure megatrends: decarbonization, digital transformation, and asset modernization while making its investments.